Product Description
PET (positron emission tomography) imaging
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Life Molecular Imaging
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01153607 |
NCT01153607 | P1 |
Completed |
Alzheimer Disease |
2011-10-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|